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Abstract
Cancer management has undergone significant improvements, which led to increased long-term survival rates among cancer 
patients. Radiotherapy (RT) has an important role in the treatment of thoracic tumors, including breast, lung, and esophageal 
cancer, or Hodgkin’s lymphoma. RT aims to kill tumor cells; however, it may have deleterious side effects on the surrounding 
normal tissues. The syndrome of unwanted cardiovascular adverse effects of thoracic RT is termed radiation-induced heart 
disease (RIHD), and the risk of developing RIHD is a critical concern in current oncology practice. Premature ischemic 
heart disease, cardiomyopathy, heart failure, valve abnormalities, and electrical conduct defects are common forms of RIHD. 
The underlying mechanisms of RIHD are still not entirely clear, and specific therapeutic interventions are missing. In this 
review, we focus on the molecular pathomechanisms of acute and chronic RIHD and propose preventive measures and pos-
sible pharmacological strategies to minimize the burden of RIHD.
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Prevention and therapy of radiation-induced heart disease
Introduction
Cardiovascular and cancerous diseases are the leading causes 
of mortality worldwide [1, 2]. The most common cancerous 
diseases are thoracic malignancies, including lung and breast 
cancers among adults [2]. Recently, cancer management has 
undergone significant improvement, leading to increased long-
term survival rates among cancer survivors. Consequently, 
age-related chronic diseases and cardiovascular risk factors, 
including hypertension, diabetes mellitus, hyperlipidemia, 
chronic kidney disease, and smoking, are often aggravated by 
chronic side effects of multimodality cancer therapy, accelerat-
ing the progression of atherosclerosis and increasing the bur-
den of cardiovascular diseases (CVDs) in cancer survivors [3].Zsuzsanna Kahán and Tamás Csont authors contributed equally to 
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While high-energy ionizing radiation successfully 
destroys cancer cells, at the same time, it may have harm-
ful effects on the surrounding healthy tissues leading to 
various side effects [4]. RT has been frequently used in 
thoracic malignancies, including breast, lung, esophageal 
cancer, thymoma, and Hodgkin’s lymphoma, which could 
be in close anatomical proximity to the heart [5]. Depending 
on the RT technique and dose, the heart may be at risk of 
being exposed to ionizing radiation resulting in radiogenic 
sequelae in a dose-dependent manner [6]. The syndrome 
of unwanted cardiovascular side effects of thoracic RT is 
called radiation-induced heart disease (RIHD), and the risk 
of development of RIHD is a critical concern in current 
oncology practice. RIHD includes structural and functional 
abnormalities of the pericardium, coronary vessels, myo-
cardium, valves, and conduction system [7, 8]. Much of 
our current knowledge on radiation-induced cardiovascular 
complications in cancer survivors is based on the patients’ 
data coming from the era of the 1980s or before that, with 
less developed RT techniques, extended RT fields, and high 
radiation doses [4, 9]. The earliest data indicating the pres-
ence of RIHD originate from follow-up studies of lymphoma 
and breast cancer patients due to the high incidence and 
high cure rate of these diseases [10, 11]. In clinical prac-
tice, the consequences of RIHD mostly emerge in breast 
cancer patients receiving left-sided postoperative RT and 
less frequently in esophageal cancer patients treated with 
preoperative chemo-radiotherapy [6].
The prevention or management of radiogenic CVDs has 
become a challenge in clinical practice since RIHD can 
worsen the outcome, quality of life, and health care costs 
in long-term cancer survivors [12, 13]. These factors have 
recently contributed to the emergence of a new specialty 
termed onco-cardiology or cardio-oncology. Unfortunately, 
therapeutic options for RIHD are currently insufficient. 
Therefore, understanding the exact molecular mechanisms 
in the progression of RIHD is necessary for developing pre-
ventive and therapeutic strategies without attenuating the 
effect of RT on cancer cells. Tailored surveillance of patients 
according to their risk status serves early intervention if nec-
essary [12, 13].
In this review, we summarize our current knowledge on 
the molecular pathomechanisms of the development and 
progression of RIHD and overview those potential pharma-
cological and other strategies that may be suitable for the 
prevention or management of RIHD.
Clinical manifestations of RIHD
RIHD may manifest in a broad spectrum of cardiovascu-
lar complications, including acute and chronic pericarditis, 
ischemic heart disease (IHD), cardiomyopathy and heart 
failure (HF), valvular heart disease, and cardiac conduc-
tion abnormalities [4, 14] (Fig. 1). Complications typically 
appear years to decades after the irradiation, showing a 
median of 10–15 years. The overall absolute risk of cardiac 
death is related to the mean heart dose (MHD) of RT [9, 15]. 
Radiation-induced cardiovascular complications are more 
severe with (i) higher total radiation dose [6], (ii) extended 
target volume exposure with closer tumor localization to 
the heart [16], (iii) younger age at the radiation exposure 
[9, 15], (iv) longer follow-up duration [17], (v) concomitant 
therapy with cardiotoxic chemotherapeutic drugs such as 
anthracyclines and biological agents [18, 19], (vi) presence 




Acute pericarditis could be the earliest form of RIHD [20] 
(Fig. 1). Before the era of selective RT-techniques in the 
late 1980s, 80% of patients receiving thoracic irradiation 
suffered from acute pericarditis [20]. In these cases, high 
MHD (> 36 Gy) administered to > 30% of the heart was 
responsible for the development of acute exudative pericar-
ditis [5, 20]. Nowadays, its occurrence is rare (< 5%) due to 
alertness and the modern heart-sparing RT-techniques [13, 
21]. Acute pericarditis causes chest pain, fever, and ECG 
abnormalities. Approximately half of the affected patients 
suffer from hemodynamic abnormalities due to significant 
pericardial effusion. Even cardiac tamponade can develop 
necessitating intervention [20].
Acute conduction system abnormalities
In the acute phase, some patients develop mostly revers-
ible asymptomatic ECG repolarization abnormalities, which 
rarely persists (the incidence is unknown due to the lack 
of screening during or shortly after RT) [14]. These events 
may occur in response to transitory circulatory/metabolic 
changes, or if irradiation induces the development of defini-
tive structural changes in the conduction system (e.g., via 
increasing oxidative/nitrosative/nitrative stress or inflam-




The presence of pericardial effusion in the acute phase might 
predispose patients to chronic pericarditis of delayed onset 
from months to years [14] (Fig. 1). Certain chemotherapeutic 
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drugs (e.g., anthracyclines, cyclophosphamide, and bleo-
mycin) may enhance the risk of radiogenic pericarditis 
development [20]. Up to 20% of patients develop chronic 
constrictive pericarditis with severe symptoms requiring 
pericardiectomy at a median time of 11 years post-irradi-
ation [22].
Ischemic heart disease (IHD)
Our understanding concerning the burden of radiogenic 
IHD is based the most on epidemiological studies [6, 8, 9, 
11, 15]. Nevertheless, estimations may be given using nor-
mal tissue complication probability models [23]. However, 
prospectively collected data with careful follow-up obser-
vations are needed [24]. In the various studies, different 
end-points, dose parameters, and statistical methods were 
used (Table 1). The studied populations also differed: some 
included all irradiated patients [8, 9, 11, 15] while others, 
only patients with major IHD events such as the need for 
coronary intervention/acute myocardial infarction (AMI) or 
IHD-related death [25, 26]. The risk of coronary artery dis-
ease (CAD) is clearly radiation dose-dependent. The tradi-
tional reference dose parameter is MHD [8, 9]. Nevertheless, 
Bogaard et al. showed that among other dose parameters, 
the volume of the left ventricle receiving at least 5 Gy (LV-
V5) is the most sensitive predictor of coronary events [27]. 
Most studies agree that beyond radiation dose, risk factors 
for CAD or the history of IHD, and young age are also deter-
minants of outcome (Table 1) [8, 9, 11, 15, 27].
Breast cancer patients receiving radiation doses of < 2 Gy, 
2–4 Gy, 5–9 Gy, and > 10 Gy had a dose-dependent excess 
risk for angina pectoris, AMI, and sudden cardiac death of 
10%, 30%, 40%, and 116%, respectively [8, 9, 27] (Table 1; 
Fig. 1). The risk for IHD increased linearly with the MHD by 
7.4% per 1 Gy absorbed dose with no apparent lower thresh-
old [8]. Similar dose–response results were found by Jacobse 
et al. in a nested case–control study: every 1 Gy increase 
in MHD was associated with a 6.4% increase in the risk of 
AMI; in MHD > 20 Gy cases, the risk of AMI was 3.4 times 
higher (Table 1) [15]. Based on modern three-dimensional 
conformal radiation therapy (3DCRT) dose-volume data, 
Bogaard et al. also confirmed these results. They introduced 
the LV-V5 parameter indicating a 1.7% increase in coronary 
events incidence by every 5 Gy increase of dose to the left 
ventricle [27]. Among lymphoma patients, identical results 
were found on MHD data and long-term AMI incidence as 
Fig. 1  Possible clinical manifestations of RIHD. RIHD is a progres-
sive disease that covers a broad spectrum of cardiac pathology. RIHD 
may manifest as acute or chronic pericarditis, conduction system 
abnormalities, ischemic heart disease, cardiomyopathy, heart failure 
including HFpEF and HFrEF, or valvular heart disease, according to 
the site of damage. LAD left descending coronary artery, LVH left 
ventricular hypertrophy, HFpEF heart failure with preserved ejection 
fraction, HFrEF heart failure with reduced ejection fraction
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clinical Research in Cardiology 
1 3
in the classic Darby-study; in MHD > 20 Gy cases, 2.5 times 
higher AMI risk was detected [9]. The dose-dependent and 
irradiated volume-dependent nature of RIHD-related sur-
vival were demonstrated in a retrospective cohort study in 
lymphoma patients with CAD requiring coronary interven-
tion [26]. The strongest predictor of a major coronary event 
is left-sided RT [28, 29]. Boekel et al. showed a significantly 
increased risk of IHD when the chest wall or the internal 
mammary nodes were irradiated independent of laterality 
in breast cancer patients [16]. The association between the 
radiation dose to a cardiac segment and the injury of the 
affected structure was demonstrated by Taylor et al. [30]. In 
this study, the highest RT doses were detected in the distal 
part of the left anterior descending (LAD) artery [30].
Cardiomyopathy and heart failure (HF)
Radiation-induced cardiomyopathy and consequent HF are 
progressive multifactorial diseases, which may evolve over 
several years (Fig. 1). They are often aggravated by medi-
cal anti-cancer therapies, concomitant radiation-induced 
valvular heart disease (VHD), or IHD. RT-induced cardio-
myopathy and HF cover a spectrum of cardiac pathological 
conditions among which a typical initial phase is HF with 
preserved ejection fraction (HFpEF). HFpEF is character-
ized by diastolic dysfunction and compensatory left ventric-
ular hypertrophy (LVH) (Fig. 1). [31–34]. Later on, progres-
sive interstitial fibrosis develops, separating and replacing 
the cardiomyocytes, which ultimately results in HF with 
reduced ejection fraction (HFrEF) [20, 35]. A tolerance dose 
of 40 Gy has been estimated for the human myocardium for 
the end-point of diffuse myocardial injury [20]. Indeed, dif-
fuse myocardial injury is more common in patients who have 
received higher RT doses (> 60 Gy) and/or anthracycline 
chemotherapy [14, 29]. Radiation-induced cardiomyopathy 
is often asymptomatic. Its risk increases 5 years after RT but 
may develop even decades after RT [20].
Valvular heart disease (VHD)
Within the first 10 years after RT, the earliest morphological 
changes appear to be leaflet thickening, fibrosis, shortening 
and calcification, and consequent regurgitation preferentially 
at the mitral or aortic valves [20] (Fig. 1). The progression 
to fibrotic thickening and calcification of the valves may 
lead to stenosis, which develops mainly in the aortic valve 
approximately 20 years after RT [20]. The rate of VHD cor-
relates better with the RT dose to the affected [36] valve 
than to the mediastinal dose [37]. Myocardial ischemia and 
hypoxia caused by IHD and fibrosis also play a role in the 
development of VHD that may contribute to HF [14].
Chronic conduction system abnormalities
In the chronic phase after irradiation, in about 5% of the 
cases, radiogenic conduction system abnormalities develop 
[37, 38]. Among these, bundle branch blocks and first-
degree atrioventricular (AV) block occur most commonly 
[39], but pathological sinus node syndrome, QTc prolonga-
tion, supraventricular arrhythmias, and ventricular extrasys-
tole or tachycardia may also develop [14, 39, 40] (Fig. 1). 
Circulatory changes such as autonomic dysfunction with 
tachycardia and blunted blood pressure, rarely syncope or 
even sudden death related to the denervation-like status of 
the heart may occur; (nevertheless, similar symptoms due to 
neck irradiation with injury of the vessels and baroreceptors 
should be distinguished) [38, 41, 42].
Late conduction anomalies may be explained with various 
pathomechanisms. Most obviously, fibrotic lesions resulted 
from decreased microvessel density, chronic hypoxia, com-
pensatory hypertrophy are behind the abnormalities [35, 
43–46]. In other cases, RT-related valvular disease and 
increased right atrial pressure cause atrial arrhythmias [38], 
or exercise-induced ischemia of the atrioventricular node 
due to the stenosis of the right coronary artery results in AV 
block [40, 47].
Pathomechanisms of RIHD
RIHD is a progressive multifactorial disease that has 
overlapping common and different molecular pathways in 
the acute and chronic phases. RT simultaneously causes 
damage to the macrovasculature (i.e., coronary arteries), 
the microvasculature, and the myocardium (i.e., diffuse 
injury) [7]. Key questions relating to the precise molecu-
lar mechanisms of the disease progression in RIHD from 
acute to chronic heart diseases remained unanswered. The 
chain of biological events from acute to chronic forms is 
more likely a complex interaction between molecular pro-
cesses. A substantial body of evidence suggests that the 
radiation-induced immediate oxidative/nitrosative/nitra-
tive damage of macromolecules, including DNA, proteins, 
and lipids, is the initiating event in RIHD. At this early 
phase, the increased oxidative/nitrative/nitrosative stress 
triggers other biological processes, including endothelial 
cell injury, acute inflammation, and the various forms of 
cell death [35, 43, 44] (Fig. 2). In the early chronic phase 
of RIHD, several compensatory mechanisms, including 
endothelial cell proliferation and cardiac hypertrophy, 
develop in the sublethally damaged surviving cells [35, 
43, 44] (Fig. 3). If these compensatory mechanisms are 
exhausted, chronic inflammatory processes, fibrosis, and 
endothelial senescence play the central role in the disease 
progression [35, 43, 44] (Fig. 3). The exact molecular 
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transition mechanisms and time points between the acute 
to compensated or decompensated chronic forms of RIHD 
are yet unknown. Moreover, several pathomechanisms, 
including oxidative/nitrative/nitrosative stress, cell death, 
and inflammatory processes, overlap during the acute and 
chronic phases of RIHD. These mechanisms could activate 
and potentiate each other leading to a vicious cycle in the 
RIHD progression. Therefore, the precise understanding of 
the complex interplay of these acute and chronic molecular 
mechanisms would help to develop strategies to counteract 
the progression of RIHD. In this section, we briefly sum-
marize the predominating pathomechanisms in which have 
a role in developing the acute and chronic forms of RIHD.
Pathomechanisms in the acute phase of RIHD
Mechanisms of increased oxidative/nitrosative/nitrative 
stress in the acute phase of RIHD
Increased oxidative/nitrosative/nitrative stress plays a cru-
cial role in developing both the desired anticancerous effects 
and the undesired side effects of RT. Absorption of ionizing 
radiation used for RT may induce both direct and indirect 
effects in all cell types [48] (Fig. 2). Ionizing radiation can 
directly disrupt atomic structures, leading to further chemi-
cal and biological changes [49] (Fig. 2). Approximately 80% 
of the cells is water. Therefore, the initial radiation-induced 
Fig. 2  Putative mechanisms in the acute phase of RIHD and potential 
pharmacological interventions. RT could induce immediate oxida-
tive/nitrosative/nitrative damage of macromolecules, including DNA, 
proteins, and lipids, in all cardiac cell types. The increased oxidative/
nitrative/nitrosative stress triggers other biological processes, includ-
ing acute inflammation, and cell death forms in the acute phase of 
RIHD in the different cell types. Parallel, hypertrophic, and fibrotic 
gene programs start in the surviving cardiomyocytes as compensa-
tory mechanisms. Potential preventive and therapeutic pharmaco-
logic agents are depicted in green boxes targeting different molecular 
mechanisms. ACEi angiotensin-converting enzyme inhibitors, Ac-
SDKP N-acetyl-Ser-Asp-Lys-Pro, ARB angiotensin receptor block-
ers, α-SMA α-smooth muscle actin, ATP adenosine triphosphate, 
Ca2+ calcium ion, Col collagen, CTGF connective tissue growth 
factor, CytC cytochrome C, ERS endoplasmic reticulum stress, FGF 
fibroblast growth factor, GHRH growth hormone-releasing hormone, 
ICAM intercellular adhesion molecules, IL interleukin, JNK c-Jun 
N-terminal kinases, ly lymphocyte, ma macrophage, MAPK mitogen-
activated protein kinase, miR microRNA, mo monocyte, Mito mito-
chondrion, NF-κB nuclear factor-κB, ng neutrophil granulocyte, NO 
nitric oxide, PACAP38 pituitary adenylate cyclase-activating poly-
peptide 38, PARP1poly-ADP-ribose-polymerase 1, PECAM platelet 
endothelial cell adhesion molecule, rhNRG-1β recombinant human 
neuregulin-1β, ROS/RNS reactive oxygen and nitrogen species, RT 
radiotherapy, TGF-β tissue growth factor-β, TNF-α tumor necrosis 
factor- α, VCAM vascular cell adhesion molecule
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cellular damage is mostly caused by the direct radiolysis of 
water generating reactive species leading to indirect effects 
[48]. The major reactive species produced in the radiolysis 
of water are superoxide  (O2•−), hydroxyl radical (•OH), elec-
trons  (e−), and hydrogen peroxide  (H2O2). Organic radicals 
 (R•) are also formed by H-abstraction reactions initiated by 
•OH radicals. These carbon-centered radicals usually react 
rapidly with  O2 to give peroxyl radicals  (RO2•), which are 
stronger oxidizing agents than their parent radicals. The 
 RO2• radicals can abstract  H• from other molecules to form 
hydroperoxides (ROOH) [48]. Ionizing radiation-induced 
tissue injury may up-regulate inducible nitric oxide syn-
thase (iNOS), thereby generating a large amount of nitric 
oxide (•NO), which can react with  O2•− to form peroxyni-
trite  (ONOO−) and secondarily other reactive nitrogen spe-
cies (RNS) [48–50] (Fig. 2). Other enzymatic sources for 
reactive oxygen species (ROS) include NADPH oxidases 
(NOX isoforms), lipoxygenases (LOX), cyclooxygenases 
(COX), peroxidases in inflammatory cells, and xanthine 
oxidase, which can be activated by RT-induced tissue injury 
[35, 48]. Ionizing radiation may also disrupt the mitochon-
drial respiratory chain contributing to persistent oxidative/
nitrosative/nitrative stress. The removal of ROS/RNS during 
RT via the key antioxidant enzymatic systems, including, 
e.g., superoxide dismutase (SOD), catalase, glutathione per-
oxidase, glutathione reductase, and heme oxygenase, may 
also be insufficient [48]. Accumulated ROS/RNS during 
and shortly after irradiation may cause macromolecular 
damage including, lipid peroxidation, protein oxidation/
nitration, inactivation of enzymes, DNA damage, interac-
tion with both DNA repair enzymes (e.g., poly-ADP-ribose 
polymerase 1 [PARP1], p53) and transcription factors (e.g., 
nuclear factor-κB [NF-κB]) [14, 20, 35, 43, 48, 51] (Fig. 2). 
Oxidative/nitrative stress can also induce acute inflamma-
tion and cell death via different mechanisms. The macro-
molecular and cellular damage may result in the activation 
of the inflammatory response (interleukins [IL] including, 
e.g., IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alpha 
[TNF-α], and transforming growth factor-beta [TGF-β]), 
stress signals (e.g., c-Jun N-terminal kinase [JNK], and p38-
MAPK) or cell death (e.g., apoptosis and necrosis), and dys-
regulation of autophagy. The oxidation/nitration of proteins 
involved in excitation–contraction coupling, contractility, 
 Ca2+-handling, elements of the mitochondrial electron trans-
port chain and Krebs cycle, metabolism, and extracellular 
matrix might result in acute and chronic deleterious events 
[14, 20, 35, 43, 48, 51] (Fig. 2).
Endothelial cell injury and acute inflammation in RIHD
Endothelial cell injury is considered the primary cause 
of radiation damage in cardiac tissue [14, 35] (Fig. 2). 
Within minutes after RT, increased vascular permeability 
and vasodilation are present [5, 35, 43]. In the first few 
hours and days after RT, activated NF-κB [52, 53] may 
induce the secretion of adhesion molecules including, e.g., 
E-selectin [54], P-selectin [54], intercellular adhesion mol-
ecule-1 (ICAM-1) [54], vascular cell adhesion molecule-1 
(VCAM-1) [55], platelet endothelial cell adhesion mol-
ecule-1 (PECAM-1) [55], and cytokines (e.g., IL-6, IL-8) 
[56, 57] in the damaged endothelial cells thereby activating 
leukocyte rolling, arrest, and transmigration [35, 43, 52]. 
The predominant inflammatory cells in the acute phase 
are neutrophil granulocytes. They infiltrate the endocar-
dium, myocardium, and epicardium of the irradiated heart. 
They are the first responders releasing pro-inflammatory 
cytokines (e.g., monocyte chemotactic protein [MCP], TNF-
α, and IL-8) to recruit other inflammatory cells [5, 43, 59] 
(Fig. 2). Recruited inflammatory cells may release further 
pro-inflammatory (e.g., IL-1, and IL-6) and pro-fibrotic 
cytokines including, e.g., TGF-β, connective tissue growth 
factor (CTGF), platelet-derived growth factor (PDGF), and 
fibroblast growth factor (FGF) [43, 58, 60–62]. Additionally, 
adhesion molecules, inflammatory and pro-fibrotic cytokines 
(e.g., ICAM-1, IL-6, and FGF) can also be produced by the 
microvascular endothelial cells suggesting their role in the 
maintenance of the pro-inflammatory state [35, 63–65]. 
Matrix metalloproteinases (MMPs), including MMP-1 and 
MMP-2, could immediately be activated by RT in endothe-
lial cells, possibly via the increased oxidative/nitrosative/
nitrative stress or inflammatory mechanisms [43, 58, 66, 
67]. These proteases may degrade the endothelial basement 
membrane, allowing effective recruitment of neutrophils and 
macrophages to cellular injury sites in order to phagocyte 
tissue debris [43, 68] (Fig. 2). The recruited inflammatory 
cells and the damaged endothelial cells can produce a large 
amount of  O2•− and •NO, the latter via iNOS, which results 
in further  ONOO− formation [58, 69]. The decreased bioa-
vailability of •NO could lead to endothelial damage, vascular 
dysfunction, vasoconstriction, and tissue hypoxia [35]. The 
mechanisms described above may lead to focal endothelial 
denudation and endothelial dysfunction, triggering initial 
arteriosclerotic lesions in larger coronary arteries [35].
Increased thrombogenicity and acute inflammation in RIHD
Initial endothelial damage in the microvasculature could also 
activate the coagulation cascade leading to fibrin deposition 
[43] (Fig. 2). Notably, it can be a result of (i) RT-induced 
endothelial damage itself [20], (ii) the thrombomodulin inhi-
bition caused by TGF-β [70], and (iii) increased release of 
von Willebrand factor (vWF) from endothelial cells [35]. 
Several coagulation factors (e.g., thrombin) may induce the 
endothelial release of IL-8 and MCP, promoting the expres-
sion of adhesion molecules and chemotaxis of neutrophil 
granulocytes [71]. RT can also activate COX and LOX 
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enzymes, which produce bioactive eicosanoids from ara-
chidonic acid, including, e.g., prostaglandins, prostacyclin, 
thromboxanes, and leukotrienes in different cell types [72]. 
These bioactive molecules are well-known mediators of 
inflammation via vasodilation or vasoconstriction, vascular 
permeability, extravasation of leukocytes, and microthrom-
bus formation [72]. Decreased bioavailability of •NO can 
lead to vasoconstriction, aggravating thrombogenicity [35].
Endoplasmic reticulum stress and apoptosis in RIHD
Irradiation can induce endoplasmic reticulum stress (ERS) 
and cell death in the different cell types of cardiac tissue, 
including cardiomyocytes, endothelial cells, fibroblasts, and 
cells of the conducting system [35] (Fig. 2). RT-induced irre-
versible damage in the structure of cellular compartments 
and molecules, mitochondrial dysfunction, and ERS are the 
critical components in cell death pathways in RIHD [14]. 
During ERS, the ER is overwhelmed with incorrectly folded 
or unfolded proteins [73]. The protein overload induces dis-
ruption of protein homeostasis and activates the unfolded 
protein response (UPR). The UPR leads to apoptotic cell 
death via three major pathways [73]. These are (i) the pro-
tein kinase R-like endoplasmic reticulum kinase (PERK)-
regulated, (ii) the activating transcription factor 6 (ATF6), 
and (iii) the inositol-requiring enzyme 1 (IRE1) pathways 
[74]. PERK inhibits protein translation via phosphorylation 
and subsequent inactivation of the eukaryotic translation 
initiator factor 2α (eIF2-α) to avoid further misfolded pro-
tein accumulation. The ATF6 and IRE1 pathways activate 
transcription of genes involved in ER-associated protein 
degradation, protein folding, and ER membrane expansion. 
IRE can also inhibit the anti-apoptotic activity of Bcl-2 and 
Bcl-XL [74]. After irradiation of cardiomyocytes, the stimu-
lated ER releases calcium ions into the cytoplasm, leading 
to mitochondrial calcium overload, cytochrome-C release 
into the cytoplasm, and activation of the pro-apoptotic Bax 
[75, 76] (Fig. 2). The translocation of Bax from the cyto-
plasm to the mitochondrial outer membrane induces mito-
chondrial membrane permeability transition (MPT), leading 
to mitochondrial swelling, depolarization of the membrane, 
uncoupled electron transport, and oxidative phosphorylation 
[75] (Fig. 2).
Necrosis in RIHD
Several death initiators, signaling pathways, and effector 
molecules are common key mediators in both apoptosis and 
necrosis [77]. Triggered by elevated oxidative/nitrosative/
nitrative stress and calcium ion toxicity after RT, the MPT 
is a causative event in cell death mechanisms, including both 
apoptosis and necrosis in cardiomyocytes [14]. Extrinsic 
stimuli via cell surface death receptors, such as TNF-α, Fas, 
and TNF-related apoptosis-inducing ligand (TRAIL) recep-
tors, can also stimulate both types of cell death [77] (Fig. 2). 
Necrotic cells release factors like endogenous mitochondrial 
damage-associated molecular patterns (DAMPs), including 
high mobility group box 1 (HMGB1), ATP, and IL-1α pro-
duced by stressed cells to evoke an inflammatory response 
[78, 79]. These signals are sensed by the nucleotide-binding 
domain and leucine-rich-repeat-containing family pyrin 3 
(NLRP3), a core protein of the inflammasome. NLRP3 acti-
vates and releases the pro-inflammatory cytokine IL-1β and 
IL-18. RT may activate NLRP3 inflammasome via multiple 
other mechanisms, including increased oxidative/nitrosative/
nitrative stress, calcium ion influx, and potassium ion efflux 
[78, 79]. NLRP3 inflammasome was suggested to play a 
critical role in the development of RIHD via its complex 
relationship with cell death and inflammatory processes [78, 
79].
Autophagy in RIHD
Autophagy, a predominantly cytoprotective catabolic pro-
cess, has been linked to apoptosis and necrosis, providing 
either a pro-survival or pro-death function [80]. The homeo-
static role of autophagy is particularly critical in terminally 
differentiated cells, including cardiomyocytes. Cytosolic 
components or cell organelles are packed into double mem-
braned autophagic vesicles that fuse with lysosomes. It 
results in the degradation and recycling of cellular compo-
nents, thereby promoting survival [77]. However, the over-
activation of autophagy could be harmful under pathologi-
cal conditions. RT can directly or indirectly damage DNA, 
which activates repairing signaling pathways. Many proteins 
participating in DNA damage repairing signaling pathways, 
such as p53, ATM, PARP1, FOXO3a, mTOR, and SIRT1, 
are involved in the regulation of autophagy (Fig. 2). Irradia-
tion may also damage extranuclear targets such as plasma 
membrane, mitochondria, and ER, leading to increased cera-
mide, ROS/RNS, and calcium ion concentrations, which can 
activate many autophagic pathways [81, 82].
Pathomechanisms in the chronic phase of RIHD
Mechanisms of the increased oxidative/nitrosative/nitrative 
stress in the chronic phase of RIHD
The early biochemical modifications, which occur during 
or shortly after the radiation exposure, were thought to be 
responsible for most of the effects of ionizing radiation in 
cells [48]. The initial oxidative/nitrative/nitrosative stress is 
caused by the radiolysis of water induced by ionizing radia-
tion (see also Sect. “Mechanism of the increased oxidative/
nitrosative/nitrative stress in the chronic phase of RHID). 
However, oxidative and nitrative changes might continue to 
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present months or years after the initial radiation exposure, 
presumably due to continuously increased generation of 
ROS/RNS via different mechanisms including, e.g., mito-
chondrial damage, inflammatory and cell death processes 
(see also Sect.“The interplay of oxidative /nitrosative/nitra-
tive stress with chronic inflammatory pathway in RIHD”.), 
overexpression of ROS-generating enzymes in cardiac tissue 
and insufficient antioxidant mechanisms [20, 48] (Fig. 3). 
Remarkably, these processes occur both in the irradiated 
cells and their progeny [48, 49]. It is also well-known that 
aging, cardiovascular risk factors (e.g., hypertension, dia-
betes mellitus, hypercholesterolemia, and chronic kidney 
disease) [83–85], and concomitant anthracycline therapy 
[86] are also associated with increased oxidative/nitrosative/
nitrative stress and low-grade chronic inflammation (Fig. 3). 
These factors might further aggravate the progression of 
RIHD.
The interplay of oxidative/nitrosative/nitrative stress 
with chronic inflammatory pathways in RIHD
In the chronic phase of inflammation, the elevated ROS/
RNS levels may result in increased expression and activity 
of TGF-β [58]. TGF-β and other growth factors (e.g., CTGF 
Fig. 3  Putative mechanisms in the chronic phase of RIHD and poten-
tial pharmacological interventions. Several pathomechanisms in 
the chronic phase of RIHD including oxidative/nitrative/nitrosative 
stress, cell death, and inflammatory processes, overlap during the 
acute and chronic phases of RIHD. These mechanisms could activate 
and potentiate each other in the different cardiac cell types leading 
to a vicious cycle. In the early chronic phase of RIHD, compensa-
tory mechanisms including manifest left ventricular hypertrophy and 
endothelial cell proliferation are predominant. If these compensatory 
mechanisms are exhausted, fibrosis and endothelial senescence play 
the central role in the late phase of disease progression. The exact 
molecular transition points from acute to compensated and decom-
pensated chronic forms of RIHD are unknown yet. Potential pre-
ventive and therapeutic pharmacologic agents are depicted in green 
boxes targeting different molecular mechanisms. ACEi angiotensin-
converting enzyme inhibitors, ARB angiotensin receptor blockers, 
α-SMA α-smooth muscle actin, ATP adenosine triphosphate, Ca2+ 
calcium ion, CaMK  Ca2+/calmodulin-dependent protein kinase, CKD 
chronic kidney disease, Col collagen, CTGF connective tissue growth 
factor, CytC cytochrome C, CV cardiovascular, ERS endoplasmic 
reticulum stress, ETC electron transport chain, FGF fibroblast growth 
factor, GHRH growth hormone-releasing hormone, JNK c-Jun N-ter-
minal kinases, ly lymphocyte, ma macrophage, MAPK mitogen-acti-
vated protein kinase, miR microRNA, mo monocyte, Mito mitochon-
drion, NF-κB nuclear factor-κB, ng neutrophil granulocyte, PACAP38 
pituitary adenylate cyclase-activating polypeptide 38, PARP1 poly-
ADP-ribose-polymerase 1, PECAM platelet endothelial cell adhesion 
molecule, ROS/RNS reactive oxygen and nitrogen species, TGF-β tis-
sue growth factor-β, TNF-α tumor necrosis factor-α
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and PDGF) promote myofibroblast differentiation, cardio-
myocyte hypertrophy, the proliferation of endothelial cells 
and fibroblasts, leading to compensatory hypertrophy with 
increased collagen deposition and remodeling in the heart 
and vessel walls, and also stenosis in the vessel lumen [58]. 
With the exacerbated atherosclerosis and reduced capillary 
network, these processes may lead to myocardial hypoxia 
and chronic ischemia, potentially resulting in cell death and, 
ultimately, HF or IHD [87] (Fig. 3). Evidence suggests that 
chronic activation of the renin–angiotensin–aldosterone 
system (RAAS) and the sympathetic nervous system in HF 
also stimulates the inflammation and oxidative/nitrosative/
nitrative stress, which factors further aggravate each other 
[88, 89]. Angiotensin II has been reported to activate car-
diac NADPH oxidase and, subsequently, the overproduction 
of ROS/RNS. The increased oxidative/nitrosative/nitrative 
stress triggers the production of pro-inflammatory media-
tors, including, e.g., IL-1, IL-6, TNF-α, and TGF-β, con-
tributing to cardiac remodeling and HF [90, 91] (Fig. 3).
Compensatory cardiac hypertrophy in RIHD
After RT-induced acute cell damage and death, a compen-
satory hypertrophy is initiated in the surviving cardiomyo-
cytes to compensate for declined cardiac function due to 
the loss of cardiomyocytes. Chronic hypoxia, inflamma-
tory pathways, and repetitive ischemia could play a role 
in the development of compensatory hypertrophy [31–34] 
(Figs. 1 and 3). Irradiation induces a significant increase in 
left ventricular wall thicknesses accompanied by reduced 
left ventricular inner diameters. In this early phase of HF, 
diastolic dysfunction develops with elevated left ventricular 
filling pressures and preserved ejection fraction (HFpEF) 
[33, 34, 92, 93]. It has also been reported that miR-212 [34], 
increased oxidative stress, TGF-β signaling, and exchange 
protein activated by cAMP (Epac) could play an essential 
role in the development of cardiac hypertrophy after RT [32, 
33]. Epac was shown to increase intracellular  Ca2+ flux, 
activate hypertrophic signals such as the  Ca2+/calmodulin-
dependent protein kinase II (CaMKII) and calcineurin, and 
induce fetal gene reprogramming independently of TGF-β-
mediated fibrotic pathways [32].
Cardiac fibrosis in RIHD
Cardiac fibrosis is considered the main late cardiac side 
effect of RT, leading ultimately to HF with reduced ejection 
fraction (HFrEF) in the decompensated phase of HF (Figs. 1 
and 3). It begins early after RT in parallel with the compen-
satory hypertrophy and might remain asymptomatic for years 
[39] (Figs. 2 and 3). Cardiac fibrosis is the result of abnor-
mally increased extracellular deposition of collagen. The 
initiation stage of fibrogenesis is driven by the RT-induced 
primary vascular endothelial cell injury. The acute changes, 
occurring within a few hours after RT, are related to cell 
death and the resulting release of acute-phase inflammatory 
response molecules (e.g., PDGF, TGF-β, basic FGF, insu-
lin-like growth factor [IGF], CTGF, IL-4, IL-13, IL-8, and 
MCP) [20, 43, 58]. The duration of the acute phase may be 
up to several days after the RT. Within 2–3 weeks after RT, 
fibrogenic effector cells, including fibroblasts, fibrocytes, 
tissue-specific pericytes, and myofibroblasts, are activated 
to differentiate into mature myofibroblasts in the second 
phase of fibrogenesis [58, 94]. The activated and terminally 
differentiated myofibroblasts secrete a high amount of type 
I, III, and IV collagens, as well as α-smooth muscle actin, 
into the extracellular matrix [43]. In this process, TGF-β is 
considered a key factor in promoting the differentiation and 
mesenchymal cells to myofibroblasts. TGF-β can activate the 
canonical SMAD2/3 and the non-canonical Rho/Rack pro-
fibrotic pathways, inhibit the collagenases, and stimulate the 
production of CTGF [20]. In the third phase of fibrogenesis, 
myofibroblasts produce a large range of extracellular pro-
teins, primarily in an autocrine manner, which may last sev-
eral weeks or months after the second phase. Myofibroblasts 
are permanently activated in the irradiated tissues even after 
repair of the initial injury. This process is driven mainly by 
TGF-β and PDGF [95]. Another factor is the ROS/RNS-
induced activation of the transcription factor NF-κB. Its acti-
vation results in increased adhesion molecule, cytokine, and 
chemokine production [43] (Fig. 3). NF-κB was shown to be 
chronically upregulated in irradiated human arterial vascular 
cells from 4 to 500 weeks after RT suggesting that it might 
play a critical role in the transition from acute to chronic 
inflammation and fibrosis [52]. The last phase of fibrogen-
esis is the manifest myocardial fibrosis developing years or 
decades after the RT. The progressive and diffuse interstitial 
fibrosis leads to decreased tissue elasticity and contractility 
as well as chronic hypoxia by separating and replacing the 
cardiomyocytes. [20, 35]. Cardiac fibrosis ultimately results 
in cell death mechanisms, organ dysfunction, and HF lead-
ing to a decompensated stage (Fig. 3).
Cellular senescence in RIHD
Cellular senescence was traditionally considered a process 
to inhibit uncontrolled replication in proliferative cells [96]. 
Nowadays, it is thought that post-mitotic cells also develop 
a senescent-like phenotype [96]. Generally, senescent cells 
become flattened, enlarged, and irreversibly lose the abil-
ity of proliferation [96]. Senescent cells produce increased 
levels of ROS/RNS, which represent increased oxidative/
nitrosative/nitrative stress to neighboring cells. Typical 
senescent cells secrete a plethora of inflammatory media-
tors (e.g., cytokines and chemokines) and extracellular pro-
teases, and the entity is named the senescence-associated 
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secretory phenotype. This phenotype leads to chronic ster-
ile inflammation and contributes to tissue remodeling [96, 
97]. The role of senescent endothelial cells seems to be 
crucial in the development of RIHD (Fig. 3). RT-induced 
endothelial senescence may involve the activation of IGF1/
phosphatidylinositol-3-kinase (PI3K)/Akt-mTOR pathway 
acting upstream of p53/p21, p38, NF-κB, and TGF-β type 
1 receptor ALK5. The induction of ERS and repression of 
telomerase reverse transcriptase are also characteristics of 
senescent endothelial cells [96, 97]. Due to the decreased 
NO bioavailability, senescent endothelial cells are incapable 
of regulating vasodilation, resulting in accelerated athero-
sclerosis and hypertension (Fig. 3). They are pro-inflam-
matory, pro-thrombotic, and pro-atherogenic due to their 
increased production of various inflammatory cytokines, 
adhesion molecules, and plasminogen activator inhibitor-1 
(PAI-1), and decreased levels of thrombomodulin (Fig. 3). 
They are also incapable of regeneration, leading to reduced 
density of cardiac capillaries and small coronary arterioles. 
The capillary rarefaction can lead to chronic cardiac hypoxia 
contributing to the RT-induced HF and IHD [96, 97].
Diagnosis and follow‑up of RIHD in patients
If needed, the early diagnosis and control of RIHD are essen-
tial since medical therapy or intervention may be of benefit. 
Control of RIHD should start with identifying individuals 
at risk for RIHD by registering heart and coronary artery 
dosimetry data. The existence of other cardiac risk factors 
such as history, age, and the use of chemotherapy, should be 
registered. In individuals at risk, clinical history and base-
line measurement of cardiac function should be recorded. 
Regular monitoring of symptoms/signs and cardiac function 
should start after RT, while in non-risk patients, the patient’s 
and physician’s alertness is sufficient [13, 24]. There has 
been an interest in testing various biomarkers of myocardial 
injury or HF, including troponin I, troponin T, B-type natriu-
retic peptide, or inflammatory cytokines such as growth dif-
ferentiation factor-15 and C-reactive protein. These may 
be used for the detection and follow-up of HF most often 
related to medical therapies, but only as a complementing 
tool of other diagnostic tools [98]. Cardiac imaging meth-
ods include echocardiography, nuclear imaging, cardio-CT, 
or MRI to serve better diagnosis [13]. Nevertheless, 2D 
speckle tracking echocardiography seems to be a sensitive 
and highly specific clinical approach for the detection of 
early subclinical heart abnormalities [98]. Cardiac SPECT 
perfusion scanning was reported to detect injury as early 
as a few months after RT [28]. The choice of the method 
may also depend on availability. For consistency reasons, 
the same expert is preferred to follow the case using the 
same diagnostic method. Different guidelines exist for the 
management of RIHD, including the follow-up of cancer 
patients after RT [12, 13, 21, 24, 99, 100]. During follow-
up, careful exploration of symptoms (notably, radiogenic 
IHD presents relatively often silent), repeated ECG, stress 
and contrast echocardiography, 3D echocardiography, stress 
perfusion imaging, tissue Doppler imaging, and screening 
for coronary calcium deposits might be applied.
Onco-cardiology follow-up in everyday practice is shown 
in Fig. 4. All guidelines recommend the specification of the 
risk-status, preferably before starting oncological treatments 
or before outlining individual follow-up strategies [12, 13, 
24]. For that, heart dose, the use of toxic oncological treat-
ments, comorbidities, and age should be considered. Accord-
ing to the risk level, follow-up should start immediately or 
many years after the RT. In high-risk patients (a mediastinal 
dose of > 30 Gy, or if anthracyclines were also given, etc.) 
monitoring should start 1–2 years post-irradiation and con-
tinue every 2 years thereafter; a great emphasis should be 
given to correcting risk factors. In low-risk cases, regular 
follow-up performed every 2–5 years started 5 years after 
the RT is considered sufficient. For the routine follow-up 
of asymptomatic patients, ECG and echocardiography are 
used. During follow-up, careful attention should be paid to 
medical history; if symptoms or suspicious signs develop, 
imaging and functional studies should be performed as pre-
viously described [12, 13, 24].
Prevention and therapy of RIHD
Currently, there are two main strategies to lessen the bur-
den caused by radiogenic heart sequelae. One is to prevent 
heart exposure as much as possible by applying new RT 
technologies and protocols [101]. Second, identifying those 
risk patients whose surveillance after RT is crucial, some-
times with comprehensive multimodality imaging-based 
screening protocols if necessary; the early diagnosis and 
non-specific management of radiation heart damage may 
effectively improve outcomes. A third possibility would 
be the application of pharmacons to protect the heart from 
radiation-induced damage. However, at present, no specific 
pharmaceutical agent is approved for the prevention or treat-
ment of RIHD in the clinics. Nevertheless, several lines of 
evidence obtained in preclinical or clinical studies suggest 
that a number of pharmacological agents might be effective 
for the treatment of RIHD.
Prevention of RIHD by cardiac dose‑sparing 
techniques
It is mandatory to individually estimate the net benefit of RT 
before its start by balancing the gains against the greatness 
of cardiac dose and the patient’s background cardiovascular 
 Clinical Research in Cardiology
1 3
risk in the absence of RT [102]. There are many approaches 
to protect the heart from radiation exposure in breast can-
cer patients [102]. Prone positioning during RT reduces 
heart doses in about 2/3 of the patients [103–105], while 
the deep-inspirational breath-holding (DIBH) technique is 
advantageous in an even higher proportion of patients [106, 
107]. Both methods operate by separating the heart and 
the radiation fields. Intensity-modulated radiation therapy 
(IMRT) and proton irradiation are advanced techniques not 
yet widely applied while reducing the volume to be irradi-
ated during partial breast irradiation (PBI), or the omittance 
of RT are options in low-risk of cancer recurrence cases. 
For the best risk–benefit ratio, the selection of individually 
tailored techniques and RT modality is needed [103, 104]. 
In non-breast cancer patients needing RT to the chest, devel-
oped techniques such as the IMRT/volumetric modulated arc 
radiotherapy (VMAT), cyberknife, or stereotactic radiosur-
gery are all based on image-guidance and particle RT. Some-
times breathing-control/gating ensure precise targeting and 
best protection of normal tissues [106]. Special consensus 
guidelines stressing the use of modern techniques, and selec-
tive RT have been elaborated for the modern RT of lym-
phoma patients [108]. RT guidelines with similar concepts 
have been published for lung cancer [109] and oesophageal 
cancer [110].
Prevention and therapy of RIHD 
with pharmacological agents
Although many agents have been tested for the prevention 
of radiation damage, none of them yet gained registration 
with this indication. Most of our knowledge in this field is 
experimental only. The group of the so-called radioprotec-
tors has anti-oxidant and/or anti-inflammatory properties 
being administered as molecular preventive strategies before 
radiation exposure [44]. The so-called mitigators are admin-
istered during or shortly after the irradiation with the aim of 
ameliorating the radiation injury of normal tissues [44]. A 
third approach is starting the protectant several weeks after 
the radiation exposure. The pharmacological treatment of 
RIHD initiated after the completion of the RT has a clear 
benefit with the advantage of not interfering with the effi-
cacy of cancer therapy but, only a few preclinical studies 
tested this approach. Despite the lack of specific treatments 
for RIHD in clinical practice, some recommendations exist 
on using standard therapies in the radiation heart sequelae 
indication (e.g., HF or IHD) [12, 13]; furthermore, some 
promising novel approaches also exist. This section collects 
well-known drugs and promising novel agents mostly tested 
in rodent RIHD models. The description of the potential 
side effects of the well-known drugs is out of the scope of 
this review.
Anti‑oxidants
Since the production of ROS/RNS is a crucial element in 
the development of acute and chronic RIHD, testing anti-
oxidants seems logical.
α-tocopherol (vitamin E)
Administration of a single dose of tocotrienols 24 h 
before the cardiac irradiation preserved the Bax/Bcl2 ratio 
and prevented mitochondrial permeability transition and 
Fig. 4  Algorithm of cardiovas-
cular follow-up after thoracic 
RT. CAD coronary artery dis-
ease, ECG electrocardiography, 
echo: echocardiography, HER2 
human epidermal growth factor 
receptor, LAD left anterior 
descending artery, RT radio-
therapy
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RT-induced alterations in the mitochondrial respiration in 
rats 2 weeks after RT [111] (Table 2). However, the single 
dose of tocotrienols could not improve the cardiac remod-
eling 28 weeks after RT [111]. In another study, the phos-
phodiesterase inhibitor pentoxifylline plus α-tocopherol 
given daily and started 1 week before the RT or 3 months 
after the RT reduced the collagen deposition in rats 6 months 
after RT [93] (Table 2). Daily administration of α-tocopherol 
plus pentoxifylline for 6 months started 3 days before the 
RT reduced collagen deposition and TGFβ1 levels in a rat 
model 6 months after the RT [112] (Table 2). However, the 
daily administration of α-tocopherol plus pentoxifylline for 
3 months started 3 days before the RT could not reduce the 
cardiac remodeling 6 months after the RT [112] (Table 2). 
In another study, the daily application of pentoxifylline and 
α-tocopherol 3 months after the RT did not alter cardiac 
fibrosis and left ventricular expression of vWF, neuregu-
lin-1, hypertrophic, and fibrotic signal mediators in rats 
6 months after the RT [113]. However, the cardiac number 
of macrophages and mast cells was reduced [113] (Table 2).
Amifostine (Ethyol)
The inactive prodrug amifostine (WR-2721) is a phos-
phorylated thiol, which can be converted to its active form 
(WR-1065) by alkaline phosphatase-catalyzed dephospho-
rylation in the vascular endothelial cells [114]. It has been 
demonstrated that amifostine protects normal tissues from 
both acute and chronic damage without interfering with the 
effects of RT on the tumor [115, 116]. Several preclinical 
studies have shown that a single dose of amifostine given 
15–30 min before irradiation could be protective against 
RT-induced cardiac fibrosis, myocardial dysfunction, and 
vascular damage 100 days or 6 months after RT [114, 117, 
118] (Table 2).
Natural products
Several natural products, including hesperidin, curcumin, 
melatonin, caffeic acid phenylethyl ester, black grape juice, 
and the ginger component zingerone, have been proposed as 
radioprotective agents due to their antioxidant and/or anti-
inflammatory properties against RIHD as reviewed recently 
[119].
Anti‑inflammatory drugs
Inflammation plays a major role in the development of 
RIHD, so it is not surprising that attenuation of the inflam-
matory response may beneficially affect the cardiac conse-
quences of RT.
Colchicine
Colchicine is known to inhibit microtubule polymeriza-
tion. Therefore, it can inhibit mitosis, neutrophil motility, 
and decrease platelet aggregation. The anti-inflammatory 
and platelet aggregation inhibiting properties of colchicine 
are suggested to be protective against RIHD [120]. However, 
there is no experimental or clinical evidence available in the 
literature for its use in RIHD.
Steroidal anti-inflammatory drugs
Reeves et al. reported that the steroidal anti-inflammatory 
drugs, dexamethasone, and methylprednisolone given 2 h 
prior to heart irradiation and every 24 h for 3 consecutive 
days reduced the cardiac fibrosis and hydroxyproline content 
in male rabbits 100 days after RT [121, 122] (Table 2).
Non-steroidal anti-inflammatory drugs (NSAIDs)
Administration of the non-selective NSAID ibuprofen 
administered 2 h prior to heart irradiation and for 2 days 
thereafter reduced fibrosis, pericarditis, pericardial effu-
sions, and improved survival in male rabbits 100 days after 
RT [122] (Table 2). It has been reported that the use of vari-
ous several non-selective COX inhibitors (e.g., ibuprofen, 
diclofenac, and naproxen) and selective COX-2 inhibitors 
(e.g., celecoxib) increased the risk of AMI [123]. There-
fore, several NSAIDs are contraindicated among patients 
with CVDs. However, there is limited data available about 
the effects of NSAIDs on the risk of AMI in patients treated 
with thoracic RT. Uehara et al. investigated the effects of 
NSAIDs, including diclofenac, etodolac, indomethacin, 
ketoprofen, meloxicam, and rofecoxib, on RT-induced 
expression of ICAM-1, VCAM-1, E-selectin, and COX-2 in 
human umbilical vein endothelial cells (HUVECs) [124]. 
They found that indomethacin, diclofenac, and meloxicam 
given 1 h before RT highly upregulated the RT-induced 
expression of ICAM-1 and COX-2 in HUVECs, suggest-
ing the potentiating effects of these NSAIDs on RT and the 
increased risk for AMI after thoracic RT [124]. The COX-2 
inhibitor celecoxib has been reported to act synergistically 
with RT in cancer cells since it attenuates tumor growth 
and expression of cell proliferation markers and induces 
apoptosis in tumor cells [125]. The increased expression of 
adhesion molecules and apoptotic effects of celecoxib or 
several NSAIDs might be responsible for the increased risk 
for AMI after RT. However, further preclinical and clinical 
studies are needed to evaluate the effects of NSAIDs on the 
development of RIHD.
Cardioprotective drugs
Cardioprotective drugs are used to lower the severity of 
consequences due to CVD risk factors under various stress 
conditions. The application of such drugs in the case of chest 
RT may be useful.
Trimetazidine
Trimetazidine is an antianginal drug that inhibits the 
beta-oxidation of fatty acids by blocking mitochondrial long-
chain 3-ketoacyl coenzyme A thiolase [126]. Trimetazidine 
also has anti-oxidant, anti-apoptotic, and inflammatory 
effects and may improve endothelial function [127]. Daily 
trimetazidine treatment started 1 week before or after chest 
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irradiation reduced cardiac fibrosis via the CTGF/TGF-β1/
Smad2/3 axis 8 weeks after the RT [127] (Table 2).
Growth hormone-releasing hormone (GHRH) and its 
agonists
The growth hormone-releasing hormone (GHRH) and its 
agonistic analogs are involved in the metabolism of reac-
tive oxygen and nitrogen species and the proliferation and 
survival of a series of normal cells, including cardiomyo-
cytes [128–130]. The administration of GHRH or GHRH 
analogs improved contractile recovery, ventricular remod-
eling during reperfusion, and reduced infarct size [131–133]. 
Similarly, two GHRH agonists, JI-34, and MR-356 showed 
increased viability and reduced ROS levels 48 h after irra-
diation in neonatal rat cardiomyocytes [134] (Table 2). How-
ever, only JI-34 could reduce the activity of the hypertrophic 
RISK/SAFE pathway [134] (Table 2).
Anti‑atherosclerotic drugs, standard IHD and HF regimens
Recent position papers of the European Society of Cardi-
ology and the German Cardiac Society summarize all the 
possible toxic effects of anti-cancer therapies on cardiovas-
cular health comprehensively and stress the need for car-
dio-oncology services [12, 13]. Endothelial dysfunction and 
atherosclerosis play an important role in the development 
of RIHD. Age and cardiovascular risk factors can further 
accelerate the atherosclerotic process in long-term cancer 
survivors. Hence, the attenuation of endothelial dysfunction 
and atherosclerosis might lower the cardiovascular conse-
quences of RT. Cancer patients presenting with clinical HF 
or IHD during or following cancer treatment need access to 
medical therapy with standard HF regimens or sometimes 
transcatheter or open surgical interventions [13]. Combined 
management with the control of age-related comorbidities 
and cardiovascular risk factors (such as hypertension, hyper-
cholesterolemia, and diabetes) is crucial [135].
Statins
The widely used statins are blood cholesterol-lowering 
drugs that inhibit the key enzyme, 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, playing an 
important role in the endogenous cholesterol synthesis 
[84]. Therefore, statins are used in the treatment of hyper-
cholesterolemia and atherosclerosis [84]. Recent studies 
showed that statins could also reduce cardiac oxidative/
nitrosative/nitrative stress, acute inflammatory reactions, 
and fibrosis via different mechanisms [136–138]. Nota-
bly, in RIHD, the inhibition of RhoA GTPase, which 
plays a crucial role in endothelial cell migration, might 
be of benefit [139]. Statins can also decrease the cardiac 
endothelial cell permeability via activating ERK5 and 
increase the release of the vasodilator NO [140]. Ostrau 
et al. showed that single doses of lovastatin given 48 and 
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adhesion molecules, pro-inflammatory and pro-fibrotic 
markers in a time-dependent manner from 24 h to 3 weeks 
after RT in rats [141] (Table 2). In a rat model of RIHD, 
daily administration of atorvastatin started 1 day before 
RT decreased the expression of the profibrotic miR-21, 
connexin-43 and PKCε in the left ventricle 6 weeks after 
the RT [138] (Table 2). Zhang et al. reported that daily 
atorvastatin treatment started 3 months before or 1 day 
after the RT improved cardiac function and reduced fibro-
sis via the repression of TGF-β1, Smad3/p-Smad3, Rho/
ROCK, p-Akt, and fibronectin in rats [142] (Table 2).
RAAS inhibitors
RAAS plays a pivotal role in the development of CVDs, 
including hypertension, atherosclerosis, AMI, cardiac hyper-
trophy, and HF, via different systemic and tissue-specific 
effects [143]. The common point in the pathophysiology of 
the various CVDs is the microvascular injury that leads to 
subsequent myocardial ischemia and late fibrous remodeling 
[143]. Clearly, the pathophysiology of RIHD is similar to 
that of other etiologies induced by angiotensin II and aldos-
terone. Cardiac concentrations of angiotensin II and aldos-
terone were dose-dependently increased 3 months after heart 
irradiation in rats [143]. Importantly, the daily administra-
tion of the angiotensin-converting enzyme (ACE) inhibitor 
captopril started on the first day after the RT ameliorated 
the perivascular and cardiac fibrosis as well as the diastolic 
dysfunction 3 months after the RT in rats [144] (Table 2). 
Another study demonstrated that daily treatments of three 
structurally-different ACE inhibitors, captopril, enalapril, 
and fosinopril, given 1 week after thoracic RT reduced pul-
monary collagen synthesis 7 months post-radiotherapy in 
rats [145] (Table 2). Although these data are interesting, 
prospective studies evaluating the efficacy of ACE inhibi-
tors in patients undergoing thoracic RT are lacking in the 
literature. The PRADA clinical trial enrolling 130 women 
with early breast cancer demonstrated that adjuvant, anthra-
cycline-containing regimens with or without trastuzumab 
and RT were associated with a modest reduction of the left 
ventricular ejection fraction (LVEF). This decline in LVEF 
was significantly alleviated by the concomitant administra-
tion of the angiotensin receptor blocker (ARB) candesartan 
[146]. In contrast, a retrospective clinical study enrolling 76 
patients undergoing coronary artery stenting after thoracic 
RT (> 30 Gy) found that ACE inhibitors or ARBs and higher 
MHD were related to lower overall survival since cancer 
diagnosis [26]. In order to clarify whether RAAS inhibitors 
may be protective against RIHD, clinical trials enrolling a 
large number of patients are required for widening the indi-
cation of this otherwise routinely used medication of heart 
failure.
Novel pharmaceutical agents
Recombinant human neuregulin-1β (rhNRG-1β)
Neuregulin-1β (NRG-1 β) binds to the tyrosine kinase 
receptors of the ErbB family, i.e., ErbB2, ErbB3, and ErbB4 
in the heart [147]. NRG-1β is critical for cardiac develop-
ment and repair, and recombinant forms are currently being 
assessed in clinical trials as possible therapeutic agents for 
systolic HF even [NCT03388593, NCT04468529]. Indeed, 
numerous preclinical studies confirmed the anti-inflamma-
tory, anti-remodeling, and anti-fibrotic effects of NRG-1 in 
the heart [148–150]. RhNRG-1β given 3 days before and 
7 days after heart irradiation decreased RT-induced myo-
cardial fibrosis and cardiomyocyte hypertrophy while pre-
serving cardiac function via the ErbB2-ERK-SIRT1 signal-
ing pathway 20 weeks after the RT in rats [151] (Table 2). 
In preclinical studies, NRG-1 was also protective against 
doxorubicin-induced or trastuzumab-induced cardiotoxic-
ity, a common unwanted side-effect related to drugs used 
in breast cancer patients [152, 153]. Although some stud-
ies have proposed that NRG1 may promote tumor growth, 
NRG1 could also act as a tumor suppressor in breast cancer 
[154, 155]. Further studies are needed to clarify the effects 
of rhNRG-1β on the tumor growth-stimulating potential of 
rhNRG-1β.
N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP)
Ac-SDKP is a ubiquitous endogenous peptide originating 
from thymosin-β4, which is essential for epicardial progeni-
tor mobilization and neovascularization [156]. Ac-SDKP 
showed anti-fibrotic and macrophage inhibitory effects via 
inhibiting the expression and activity of a carbohydrate-
binding surface protein, Mac-2 (galectin-3), in preclini-
cal models [157, 158]. Ac-SDKP administered daily for 
18 weeks after thoracic RT inhibited inflammation, fibrosis, 
and reduced macrophage activation in rats [156] (Table 2).
Pituitary adenylate cyclase-activating polypeptide 38 
(PACAP38)
The endogenous peptide PACAP38 is a member of the 
secretin/vasoactive intestinal peptide (VIP) family. It has 
anti-inflammatory, anti-apoptotic, and antioxidant effects 
in cardiomyocytes [159, 160]. PACAP38 was radioprotec-
tive in H9c2 cardiomyoblasts via anti-apoptotic effects and 
the overexpression of the nuclear factor erythroid 2-related 
factor 2 (NRF2), which is a key factor in the expression 
of antioxidant enzymes [159]. PACAP38 given 2 h before 
irradiation, and at 24 h and 48 h after irradiation reduced 
apoptosis and cardiac fibrosis 21 days after the RT in male 
C57BL6 mice [159] (Table 2).
Potential anti-inflammatory and anti-fibrotic biological 
therapies
A common mechanism in the pathophysiology of HF 
and IHD of non-radiation etiology is chronic inflammation 
and fibrosis. So far, no anti-inflammatory or anti-fibrotic 
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biological therapy has been tested in RIHD in clinical tri-
als. However, some anti-inflammatory agents, including, 
e.g., the IL-1 receptor antagonist anakinra (clinical tri-
als NCT03797001, NCT01175018, and NCT02547766) 
or the IL-6 receptor antagonist tocilizumab (clinical trial 
NCT01491074), have been already tested against post-
infarction remodeling and HF in phase 2 clinical trials. 
Interestingly, the human anti-CTGF antibody (FG-3019) 
started at different time points before or after thoracic irra-
diation ameliorated the pulmonary remodeling in a mice 
model [161]. However, anti-CTGF antibodies have not been 
tested in the clinical phase in RIHD yet. The TGF-β recep-
tor-1 antagonist IPW-5371 administered orally 24 h after 
the radiation exposure and daily after that for 6 or 20 weeks 
was reported to mitigate the injury of RT (5 Gy total body 
irradiation plus 6.5 Gy thoracic irradiation) in C57BLJ 
mice [162]. IPW-5371 treatment for both 6 and 20 weeks 
improved survival. The 20-week therapeutic regimen pre-
served arterial oxygen saturation with significant decreases 
in breathing frequency. It reserved the cardiac contractile 
function and ameliorated cardiac and pulmonary fibrosis 
[162]. IPW-5371 treatment decreased p-Smad3 tissue levels, 
confirming the effect of IPW-5371 on TGF-β signaling [162] 
(Table 2). IPW-5371 is not yet in the clinical phase, but 
another TGF-β1 receptor inhibitor, the orally bioavailable 
galunisertib (LY2157299), has already been tested in phase 
II clinical trials in metastatic breast cancer patients in com-
bination with RT (NCT02538471), hepatocellular carcinoma 
(NCT02178358), and pancreatic cancer (NCT01373164).
Cardiac‑specific drug delivery
Radioprotective agents may interfere with the anti-cancer 
effects of RT. Therefore, the development of cardiac-
specific drug delivery techniques (e.g., liposomes, poly-
meric micelles, biodegradable nanoparticles, dendrimers, 
exosomes, plasmids, or other vectors) [163]. would be of 
interest in order to selectively protect the heart from ionizing 
radiation and thus preventing RIHD. Several drugs, includ-
ing VEGF delivered by plasmids or adenoviruses to the 
heart, have already been tested in HF and AMI in clinical tri-
als (NCT03409627, NCT01002430, NCT04125732, respec-
tively). Unfortunately, up to now, no major breakthrough has 
been achieved in the field of targeted drug delivery for the 
prevention of RIHD.
Gene expression regulators as potential new 
therapeutic targets: non‑coding RNAs
The gene expression is regulated at different levels, includ-
ing the post-transcriptional regulation by non-coding 
RNAs (ncRNAs). The ncRNAs are classified as i) longer 
ncRNAs such as long non-coding RNAs (lncRNAs) and 
circular RNAs (circRNAs), ii) and short ncRNAs (19–22 
nucleotides) such as microRNAs (miRs) and small interfer-
ing RNAs (siRNAs) [164]. At present, literature data are 
available on the role of miRs only in the development of 
RIHD. miRs are thought to be tissue-specific fine-tuners 
of gene expression in biological processes, including those 
related to oxidative/nitrative stress, cell death, cell prolif-
eration and development, and inflammation [165]. Hence, 
dysregulation of miRs in pathological processes, including 
RIHD, may alter whole gene networks rather than single 
genes. The major difference between miRs and siRNAs 
is that siRNAs are highly specific for one mRNA target, 
whereas miRs have multiple targets. Consequently, miR 
replacement or blockade with anti-sense inhibition therapy 
may offer a new approach to treat diseases by modulating 
complex gene pathways [166]. However, at present, the use 
of miRs as therapeutic targets or biomarkers has many limi-
tations. A specific miR can target several mRNAs, and dif-
ferent miRs can target a particular mRNA in many tissue 
types. Therefore, potentially harmful effects of miR-based 
drugs (antagomiRs or agomiRs) could originate not only 
from off-target side effects (e.g., unwanted gene expression 
changes) but also from on-target side effects in non-targeted 
and non-diseased tissues [167]. In pre-clinical studies, cel-
lular senescence-associated miR-34 [168], and pro-fibrotic 
miR-21 [169] were repressed, and the anti-fibrotic miR-15 
[169] was overexpressed in the heart. These miRs seems to 
be promising in the future treatment of RIHD [138, 169]. 
Since the miR expression profile can be tissue-specific, the 
circulating miR profile may reflect the severity of radiation 
damage and correlate with the risk for the development of 
late organ-specific complications after RT. A clinical study 
enrolling breast cancer patients demonstrated the associa-
tion between the circulating levels of the atherosclerosis-
associated miR-146a, miR-155, miR-221, and miR-222 and 
later development of RT-induced cardiovascular complica-
tions [170]. Another clinical study found in non-small cell 
lung cancer NSCLC patients that the decrease of circulating 
miR-29a-3p and miR-150-5p levels was correlated with the 
RT dose delivered to the chest [171].
Conclusions and perspectives
Much has been learned about the pathomechanism and clini-
cal significance of RIHD in the past decades. All forms of 
radiation heart damage are dose-dependent and volume-
dependent progressive alterations that should be prevented 
or, if manifest, should be early diagnosed and effectively 
treated to prevent definitive deterioration or fatal outcome. 
The key-event is cellular damage that results in cell loss and 
initiates inflammation and fibrosis, which may affect any of 
the structures of the heart. Although experimental in vitro 
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and in vivo models have been used to study the patho-
physiology of RIHD, the exact molecular mechanisms in 
the development of acute and chronic phases and the cross-
talk between them are still not entirely clear. Future in vivo 
models that would better reflect clinical situations such as 
the presence of cardiovascular comorbidities or cancer, the 
modulatory effects of multimodality cancer therapy, and sex-
based differences are much-needed. At present, there are no 
specific drugs approved for the prevention or treatment of 
RIHD. To lessen the burden that RT may cause to patients 
needing chest irradiation, the consideration and control of 
radiation dose to normal tissues and the use of individually 
selected RT techniques is essential. Obviously, prospec-
tive clinical trials are needed for the identification of novel 
predictors of radiation heart damage, new models, and new 
guidelines for optimal heart sparing. Future developments 
in cardiac-specific drugs or selective administration tech-
niques, as well as personalized therapeutic approaches, are 
also essential for effectively reduce cardiovascular adverse 
effects following thoracic RT. Tailored monitoring of radia-
tion heart sequelae based on individual risk-status within the 
frame of multidisciplinary onco-cardiology teamwork would 
enhance early intervention if needed.
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